Cargando…

Derivation and Validation of a Screening Model for Hypertrophic Cardiomyopathy Based on Electrocardiogram Features

BACKGROUND: Hypertrophic cardiomyopathy (HCM) is a widely distributed, but clinically heterogeneous genetic heart disease, affects approximately 20 million people worldwide. Nowadays, HCM is treatable with the advancement of medical interventions. However, due to occult clinical presentations and a...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Lanyan, Gao, Chao, Yang, Weiping, Ma, Zhiling, Zhou, Mengyao, Liu, Jianzheng, Shao, Hong, Wang, Bo, Hu, Guangyu, Zhao, Hang, Zhang, Ling, Guo, Xiong, Huang, Chong, Cui, Zhe, Song, Dandan, Sun, Fangfang, Liu, Liwen, Zhang, Fuyang, Tao, Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170889/
https://www.ncbi.nlm.nih.gov/pubmed/35686042
http://dx.doi.org/10.3389/fcvm.2022.889523
_version_ 1784721531622916096
author Guo, Lanyan
Gao, Chao
Yang, Weiping
Ma, Zhiling
Zhou, Mengyao
Liu, Jianzheng
Shao, Hong
Wang, Bo
Hu, Guangyu
Zhao, Hang
Zhang, Ling
Guo, Xiong
Huang, Chong
Cui, Zhe
Song, Dandan
Sun, Fangfang
Liu, Liwen
Zhang, Fuyang
Tao, Ling
author_facet Guo, Lanyan
Gao, Chao
Yang, Weiping
Ma, Zhiling
Zhou, Mengyao
Liu, Jianzheng
Shao, Hong
Wang, Bo
Hu, Guangyu
Zhao, Hang
Zhang, Ling
Guo, Xiong
Huang, Chong
Cui, Zhe
Song, Dandan
Sun, Fangfang
Liu, Liwen
Zhang, Fuyang
Tao, Ling
author_sort Guo, Lanyan
collection PubMed
description BACKGROUND: Hypertrophic cardiomyopathy (HCM) is a widely distributed, but clinically heterogeneous genetic heart disease, affects approximately 20 million people worldwide. Nowadays, HCM is treatable with the advancement of medical interventions. However, due to occult clinical presentations and a lack of easy, inexpensive, and widely popularized screening approaches in the general population, 80–90% HCM patients are not clinically identifiable, which brings certain safety hazards could have been prevented. The majority HCM patients showed abnormal and diverse electrocardiogram (ECG) presentations, it is unclear which ECG parameters are the most efficient for HCM screening. OBJECTIVE: We aimed to develop a pragmatic prediction model based on the most common ECG features to screen for HCM. METHODS: Between April 1st and September 30th, 2020, 423 consecutive subjects from the International Cooperation Center for Hypertrophic Cardiomyopathy of Xijing Hospital [172 HCM patients, 251 participants without left ventricular hypertrophy (non-HCM)] were prospectively included in the training cohort. Between January 4th and February 30th, 2021, 163 participants from the same center were included in the temporal internal validation cohort (62 HCM patients, 101 non-HCM participants). External validation was performed using retrospectively collected ECG data from Xijing Hospital (3,232 HCM ECG samples from January 1st, 2000, to March 31st, 2020; 95,184 non-HCM ECG samples from January 1st to December 31st, 2020). The C-statistic was used to measure the discriminative ability of the model. RESULTS: Among 30 ECG features examined, all except abnormal Q wave significantly differed between the HCM patients and non-HCM comparators. After several independent feature selection approaches and model evaluation, we included only two ECG features, T wave inversion (TWI) and the amplitude of S wave in lead V1 (SV1), in the HCM prediction model. The model showed a clearly useful discriminative performance (C-statistic > 0.75) in the training [C-statistic 0.857 (0.818–0.896)], and temporal validation cohorts [C-statistic 0.871 (0.812–0.930)]. In the external validation cohort, the C-statistic of the model was 0.833 [0.825–0.841]. A browser-based calculator was generated accordingly. CONCLUSION: The pragmatic model established using only TWI and SV1 may be helpful for predicting the probability of HCM and shows promise for use in population-based HCM screening.
format Online
Article
Text
id pubmed-9170889
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91708892022-06-08 Derivation and Validation of a Screening Model for Hypertrophic Cardiomyopathy Based on Electrocardiogram Features Guo, Lanyan Gao, Chao Yang, Weiping Ma, Zhiling Zhou, Mengyao Liu, Jianzheng Shao, Hong Wang, Bo Hu, Guangyu Zhao, Hang Zhang, Ling Guo, Xiong Huang, Chong Cui, Zhe Song, Dandan Sun, Fangfang Liu, Liwen Zhang, Fuyang Tao, Ling Front Cardiovasc Med Cardiovascular Medicine BACKGROUND: Hypertrophic cardiomyopathy (HCM) is a widely distributed, but clinically heterogeneous genetic heart disease, affects approximately 20 million people worldwide. Nowadays, HCM is treatable with the advancement of medical interventions. However, due to occult clinical presentations and a lack of easy, inexpensive, and widely popularized screening approaches in the general population, 80–90% HCM patients are not clinically identifiable, which brings certain safety hazards could have been prevented. The majority HCM patients showed abnormal and diverse electrocardiogram (ECG) presentations, it is unclear which ECG parameters are the most efficient for HCM screening. OBJECTIVE: We aimed to develop a pragmatic prediction model based on the most common ECG features to screen for HCM. METHODS: Between April 1st and September 30th, 2020, 423 consecutive subjects from the International Cooperation Center for Hypertrophic Cardiomyopathy of Xijing Hospital [172 HCM patients, 251 participants without left ventricular hypertrophy (non-HCM)] were prospectively included in the training cohort. Between January 4th and February 30th, 2021, 163 participants from the same center were included in the temporal internal validation cohort (62 HCM patients, 101 non-HCM participants). External validation was performed using retrospectively collected ECG data from Xijing Hospital (3,232 HCM ECG samples from January 1st, 2000, to March 31st, 2020; 95,184 non-HCM ECG samples from January 1st to December 31st, 2020). The C-statistic was used to measure the discriminative ability of the model. RESULTS: Among 30 ECG features examined, all except abnormal Q wave significantly differed between the HCM patients and non-HCM comparators. After several independent feature selection approaches and model evaluation, we included only two ECG features, T wave inversion (TWI) and the amplitude of S wave in lead V1 (SV1), in the HCM prediction model. The model showed a clearly useful discriminative performance (C-statistic > 0.75) in the training [C-statistic 0.857 (0.818–0.896)], and temporal validation cohorts [C-statistic 0.871 (0.812–0.930)]. In the external validation cohort, the C-statistic of the model was 0.833 [0.825–0.841]. A browser-based calculator was generated accordingly. CONCLUSION: The pragmatic model established using only TWI and SV1 may be helpful for predicting the probability of HCM and shows promise for use in population-based HCM screening. Frontiers Media S.A. 2022-05-24 /pmc/articles/PMC9170889/ /pubmed/35686042 http://dx.doi.org/10.3389/fcvm.2022.889523 Text en Copyright © 2022 Guo, Gao, Yang, Ma, Zhou, Liu, Shao, Wang, Hu, Zhao, Zhang, Guo, Huang, Cui, Song, Sun, Liu, Zhang and Tao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Guo, Lanyan
Gao, Chao
Yang, Weiping
Ma, Zhiling
Zhou, Mengyao
Liu, Jianzheng
Shao, Hong
Wang, Bo
Hu, Guangyu
Zhao, Hang
Zhang, Ling
Guo, Xiong
Huang, Chong
Cui, Zhe
Song, Dandan
Sun, Fangfang
Liu, Liwen
Zhang, Fuyang
Tao, Ling
Derivation and Validation of a Screening Model for Hypertrophic Cardiomyopathy Based on Electrocardiogram Features
title Derivation and Validation of a Screening Model for Hypertrophic Cardiomyopathy Based on Electrocardiogram Features
title_full Derivation and Validation of a Screening Model for Hypertrophic Cardiomyopathy Based on Electrocardiogram Features
title_fullStr Derivation and Validation of a Screening Model for Hypertrophic Cardiomyopathy Based on Electrocardiogram Features
title_full_unstemmed Derivation and Validation of a Screening Model for Hypertrophic Cardiomyopathy Based on Electrocardiogram Features
title_short Derivation and Validation of a Screening Model for Hypertrophic Cardiomyopathy Based on Electrocardiogram Features
title_sort derivation and validation of a screening model for hypertrophic cardiomyopathy based on electrocardiogram features
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170889/
https://www.ncbi.nlm.nih.gov/pubmed/35686042
http://dx.doi.org/10.3389/fcvm.2022.889523
work_keys_str_mv AT guolanyan derivationandvalidationofascreeningmodelforhypertrophiccardiomyopathybasedonelectrocardiogramfeatures
AT gaochao derivationandvalidationofascreeningmodelforhypertrophiccardiomyopathybasedonelectrocardiogramfeatures
AT yangweiping derivationandvalidationofascreeningmodelforhypertrophiccardiomyopathybasedonelectrocardiogramfeatures
AT mazhiling derivationandvalidationofascreeningmodelforhypertrophiccardiomyopathybasedonelectrocardiogramfeatures
AT zhoumengyao derivationandvalidationofascreeningmodelforhypertrophiccardiomyopathybasedonelectrocardiogramfeatures
AT liujianzheng derivationandvalidationofascreeningmodelforhypertrophiccardiomyopathybasedonelectrocardiogramfeatures
AT shaohong derivationandvalidationofascreeningmodelforhypertrophiccardiomyopathybasedonelectrocardiogramfeatures
AT wangbo derivationandvalidationofascreeningmodelforhypertrophiccardiomyopathybasedonelectrocardiogramfeatures
AT huguangyu derivationandvalidationofascreeningmodelforhypertrophiccardiomyopathybasedonelectrocardiogramfeatures
AT zhaohang derivationandvalidationofascreeningmodelforhypertrophiccardiomyopathybasedonelectrocardiogramfeatures
AT zhangling derivationandvalidationofascreeningmodelforhypertrophiccardiomyopathybasedonelectrocardiogramfeatures
AT guoxiong derivationandvalidationofascreeningmodelforhypertrophiccardiomyopathybasedonelectrocardiogramfeatures
AT huangchong derivationandvalidationofascreeningmodelforhypertrophiccardiomyopathybasedonelectrocardiogramfeatures
AT cuizhe derivationandvalidationofascreeningmodelforhypertrophiccardiomyopathybasedonelectrocardiogramfeatures
AT songdandan derivationandvalidationofascreeningmodelforhypertrophiccardiomyopathybasedonelectrocardiogramfeatures
AT sunfangfang derivationandvalidationofascreeningmodelforhypertrophiccardiomyopathybasedonelectrocardiogramfeatures
AT liuliwen derivationandvalidationofascreeningmodelforhypertrophiccardiomyopathybasedonelectrocardiogramfeatures
AT zhangfuyang derivationandvalidationofascreeningmodelforhypertrophiccardiomyopathybasedonelectrocardiogramfeatures
AT taoling derivationandvalidationofascreeningmodelforhypertrophiccardiomyopathybasedonelectrocardiogramfeatures